geva – Scalper1

Alexion’s $8.4 Billion Synageva Buyout Spooks Street

Big-cap biotech Alexion Pharmaceuticals on Wednesday agreed to pay $8.4 billion in cash and stock for fellow rare-disease specialist Synageva BioPharma, a price that investors greeted with trepidation. Alexion’s stock fell 8% to close at 155.01, while Synageva’s soared 112% to 203.39. Alexion (ALXN) agreed to pay $115 in cash and 0.6581 Alexion share for every Synageva (GEVA) share, which at Alexion’s nine-day volume-weighted average closing price

Alexion Buying Synageva For $230 A Share; Stock Slips

Big-cap biotech Alexion Pharmaceuticals (ALXN) agreed to pay $8.4 billion in cash and stock for fellow rare-disease specialist Synageva BioPharma (GEVA) Wednesday, which at $230 a share was more than twice Synageva’s closing price. Alexion stock dipped and Synageva soared in early trading. Alexion agreed to pay $115 in cash and 0.6581 Alexion share for every Synageva share, in a bid to diversify from its sole marketed product, Soliris. Alexion is